Schrodinger
SDGR · NASDAQ · Healthcare
$29.23
$0.98 (-3.34%) today
Market Cap
$2.19B
24h Volume
$89.5M
P/E Ratio
-11.4
52w High
$30.24
52w Low
$11.07
Est. AI Revenue
75%
7-Day Sparkline (Static)
Company facts
Performance
About Schrodinger
Schrodinger is a computational chemistry company. It licenses physics based software that simulates how molecules behave, letting pharmaceutical and materials companies test drug candidates on computers instead of running every experiment in a wet lab. It also uses the same platform for its own drug programs and partnerships.
Its products include the Schrodinger Platform for molecular simulation, FEP+ for predicting how tightly a drug binds its target, LiveDesign for collaborative drug design, and AI molecular simulations that combine physics models with machine learning.
Founded in 1990 and headquartered in New York City, Schrodinger trades on the NASDAQ and employs about 850 people under CEO Ramy Farid.
Schrodinger in the AI buildout
Schrodinger sits in the AI Healthcare layer of the buildout, with a platform business in AI Software & Platforms. Its entire franchise rests on the idea that simulation and machine learning can replace wet lab screening in drug discovery, so computational methods are not a feature, they are the product. It monetizes this through software licenses to pharma and through its own drug programs, which is why Supercycle scores its AI exposure at 75 out of 100.
SDGR is tracked in AI Healthcare and AI Software & Platforms, rated Core on the AI Exposure leaderboard.
By the numbers
52-week range
SDGR trades at $29.23, 95% of the way up its 52-week range of $11.07 to $30.24.
Market cap
Market capitalization is $2.19B, with an AI Exposure Score of 75 out of 100.
Next earnings
Schrodinger is next expected to report earnings on November 4, 2026.
Market data as of the close on . Prices are end of day, not live.
Frequently asked questions
What does Schrodinger do?
Schrodinger licenses physics based computational chemistry software that simulates molecular behavior, letting pharma companies test drug candidates digitally. It also runs its own drug discovery programs on the same platform.
How is Schrodinger exposed to AI?
Deeply. The whole franchise rests on simulation and machine learning replacing wet lab screening, so computational discovery is the thesis itself. Supercycle scores its AI exposure at 75 out of 100.
What are Schrodinger's main products?
The Schrodinger Platform for molecular simulation, FEP+ for binding predictions, LiveDesign for collaborative drug design, and AI molecular simulation tools that pair physics models with machine learning.
Who leads Schrodinger and where is it based?
CEO Ramy Farid leads the company from New York City. Founded in 1990, Schrodinger employs about 850 people and trades on the NASDAQ.
What sector and categories is SDGR in?
Schrodinger is a Healthcare sector company. On Supercycle it is categorized under AI Healthcare and AI Software & Platforms within the AI buildout map.
Profile written 2026-08, updated as the business changes. Editorial content, not investment advice.